Kornimate/medical-research-clean huggingface dataset:
ambulatory oxygen for ild

Conditions: Interstitial Lung Disease

Summary: people with interstitial lung disease (ild) are frequently prescribed ambulatory oxygen, to increase oxygen levels in the blood during daily activities. the best way of delivering this type of oxygen has not been established. the aim of this study is to compare two devices for delivering oxygen in people with interstitial lung disease - the traditional method using portable cylinders and a newer method using a portable concentrator. the investigators hypothesise that oxygen levels during exercise will be significantly higher when using a portable cylinder, but this difference will be small.

exercise-induced hypoxaemia (eia) is very common in individuals with ild, due to progressive lung fibrosis which results in impaired gas exchange. it is common for people with eia to be prescribed ambulatory oxygen, in order to normalize oxyhaemoglobin saturation, improve oxygen delivery to the tissues and relieve breathlessness during daily activities. ambulatory oxygen is traditionally delivered via a refillable portable oxygen cylinder containing compressed gaseous oxygen. more recently, portable oxygen concentrators (pocs) have emerged as a solution to the problem of finite cylinder life and to improve portability. because a concentrator is constantly extracting oxygen from air, oxygen supply can continue as long as the battery is charged. this is typically around eight hours, but pocs can be recharged from an ac or dc power source. portable oxygen concentrators usually weigh around 3.5kg, which is significantly lighter than oxygen cylinders, and are much easier to maneuver. however, there are some theoretical disadvantages to pocs. like all concentrators, they do not deliver 100% oxygen. concentrations typically range from 85-95%, depending on the flow rate. differences in pulse timing and peak pulse flow between pocs may affect the fraction of inspired oxygen (fio2) that is delivered. however, the clinical implications of these differences have not been documented. the aim of this study is to compare the effects of ambulatory oxygen delivered during exercise using the evergo poc to ambulatory oxygen delivered with a standard portable cylinder in individuals with ild. we hypothesise that oxyhaemoglobin saturation during exercise will be significantly higher when using a portable cylinder, but this difference will not be clinically important.

Eligibility criteria:
inclusion criteria: * a confident diagnosis of ild made according to established criteria and * desaturate to less than 90% during a 6-minute walk test exclusion criteria: * primary diagnosis of a respiratory condition other than ild (eg copd) * currently using continuous oxygen therapy * oxyhaemoglobin saturation (spo2) is less than 90% on room air * unable to perform a 6-minute walk test or comorbidities that limit walking

Keywords: interstitial lung disease oxygen therapy walk
osteopathic manipulation makes a neuropsychological difference

Conditions: Cognitive Change; Musculoskeletal Pain

Summary: patients with pain commonly experience cognitive impairment. while symptoms of pain are effectively treated with osteopathic manipulative treatment (omt), the cognitive piece is vastly ignored. pain-induced cognitive dysfunction can be severe and is particularly apparent in working memory and attention. there is good reason to also expect cognitive responsiveness to omt. previous research has already reported related psychiatric outcomes, including relief from stress, self-perception and anxiety, suggesting that omt may produce more global effects on cortical processing than currently thought.

patients with pain commonly experience cognitive impairment. while symptoms of pain are effectively treated with osteopathic manipulative treatment (omt), the cognitive piece is vastly ignored. previous research has already reported related psychiatric outcomes, including relief from stress, self-perception and anxiety, suggesting that omt may produce more global effects on cortical processing than currently thought. the current study is designed to extend previous research in several ways: 1. to describe the neuropsychological (np) characteristics of adults with pain within an osteopathic and allopathic setting 2. to correlate np with clinical outcomes (pain severity, number/location of osteopathic lesions) 3. to determine if omt is associated with improved np function. 4. to use saliva to measure cytokine concentration of il-1β,il-6, il-8, tnf-α 5. to correlate cytokine concentrations with clinical outcomes (pain severity, number/location of osteopathic lesions, np)

Eligibility criteria:
inclusion criteria: 1. 40 years of age or older; 2. seeking treatment for acute or chronic pain (neck, thoracic, shoulder, back) 3. gives a positive response to the item, "have you had thinking problems because of your pain?"; 4. agree to forego extra-trial manipulation (e.g., massage, chiropractic, physical therapy); 5. score \> 23 on the telephone interview for cognitive status; 6. written informed consent. exclusion criteria: 1. recent (\< 2 month) or planned surgery within the duration of the study; 2. use of medication that could interfere with cytokine measurements; 3. recent (\< 2 month) changes to psychotropic medication within the duration of the study; 4. history of manipulation within the past six months. 5. diagnosed neurocognitive disorders; 6. contraindication to receiving omt.

Keywords: cognitive decline pain osteopathic manipulative treatment
therapeutic effect of cassia seed in obesity of patients with schizophrenia

Conditions: Schizophrenia

Summary: schizophrenia patients with anti-psychotics have decreased psychiatric symptoms, but have increased the generation of overweight or obesity. there is correlation between obesity, diabetes mellitus, metabolic syndrome, hypertension, hyperlipidemia and cardiovascular disorders. cassia seed is one of traditional chinese herbs, that can decline blood lipedema effect. therefore, the purpose of the present study was to design a randomized, double blind, control group study to assess the therapeutic effect of cassia seed in schizophrenia patients with obesity.

total of 92 schizophrenia patients with obesity will be enrolled and divided randomly into: 1) case group, received oral administration of cassia seed (3.0g), once/day, 12 weeks; 2) control group, received oral administration of cassia seed placebo (3.0g), once/day (90% of starch and 10% of cassia obtusifolia), 12 weeks. the primary outcome included the changes of body mass index (bmi), waist circumferences (wc); secondary outcome measured included the changes of hemoglobin a1c (hba1c), total cholesterol, triglyceride, high density lipoprotein, low density lipoprotein, crp (c-reactive protein), il-6, systolic blood pressure, diastolic blood pressure, and meridian energy.

Eligibility criteria:
inclusion criteria: * age 18 to 65 years * diagnosed as schizophrenia at least more 6 months * no major systemic illnesses based on physical examinations and laboratory test results * bmi \>= 24, wc \>= 80 cm in female, wc \>= 90 cm in male exclusion criteria: * participants were pregnant and lactating women * allergy to cassia * sgot or sgpt more than 2 times normal level * bun or creatinine more than normal level * fasting blood glucose (serum) \> 140 mg/dl, systolic blood pressure \> 180 mmhg, diastolic blood pressure \> 110 mmhg, serum triglyceride \> 400 mg/dl

Keywords: schizophrenia cassia seed obesity therapeutic effect assessment clinical trial
predicting hospitalized infection in patients with chronic inflammatory arthritis treated with biological drugs

Conditions: Rheumatoid Arthritis; Spondyloarthritis; Psoriatic Arthritis

Summary: background the risk for hospitalized infection (i.e. infection leading to hospitalization) in patients with inflammatory arthritis (rheumatoid arthritis (ra), psoriatic arthritis (psa) or axial spondyloarthritis (axspa) treated with biological drugs is known to be increased compared to the background population. in daily clinical practice, there is a need for a simple way to assess the absolute risk for hospitalized infection in individual patients based on easily available information such as age, diagnosis, functional status, comorbidities and medication. this risk estimate will be useful in clinical decision making e.g. when advising patients on whether or not to initiate biologic therapy or when advising patients on influenza or pneumococcal vaccination. objectives the objectives are 1) to assess the risk for hospitalized infection (infection leading to hospitalization) in patients with inflammatory arthritis during 12 months of follow-up after initiating treatment with their first biological drug (bdmard) with the risk in the general population, and 2) to develop a simple, clinically useful algorithm that allows prediction of the risk of hospitalized infection in individual patients. methods observational cohort study based on existing data in: the danish rheumatology register (danbio), the danish national patient register, the danish national prescription register and the danish register of causes of death. all patients registered in danbio with ra, psa or axspa who initiated treatment with their first biological drug between january 1, 2006 and december 31, 2016 will be identified. baseline predictors and outcomes (hospitalized infection or death) during 12 months of follow-up are obtained. logistic regression analysis and 10-fold cross-validation will be used to develop and internally validate the prediction model.


Eligibility criteria:
inclusion criteria: * patients with ra: registered in danbio with a diagnosis of m05.9, m06.0 or m06.9. * patients with spa: registered in danbio with a diagnosis of m45.9, m46.1, m46.8+m02.9, m46.8+m07.4, m46.8+m07.5 or m46.9. * patients with psa: registered in danbio with a diagnosis of m07.3 or m46.8+m07.2. * first bdmard treatment course. * start of treatment with first bdmard in the period january 1, 2006 to december 31, 2016. * age at start of treatment with first bdmard ≥ 18 years. exclusion criteria: - not followed in danbio since start of first bdmard.

Keywords: hospitalization infection
the effect of light therapy on post-surgical pain

Conditions: Intensive Care Unit; Cardiac Surgery

Summary: researchers aim to demonstrate that the use of phototherapy is feasible and may reduce acute postoperative pain based on recent literature. the primary objective is to demonstrate that displaying light-emitting diodes \[led\] can be achieved in the icu setting in after cardiac surgery.

the primary aim of this study to determine whether or not green light phototherapy is feasible after cardiac surgery. patients that will be undergoing heart surgery will be recruited to the study. after surgery they will be exposed to either green or white leds for up to 5 hours per day and up to one week after surgery. after their exposure to light therapy, a survey will be given to the patient which will ask questions regarding tolerance of the therapy. a survey will also be given to the staff which will query whether or not the therapy was an impediment to workflow. in addition, the medical record will be reviewed to assess opiate usage in each group as an exploratory aim which may suggest differences in pain experiences.

Eligibility criteria:
inclusion criteria: - status post heart surgery and are admitted in the icu at mayo clinic, florida. exclusion criteria: * patient with color blindness and/or untreated cataracts. * patients who are hemodynamically unstable. * patients with dementia/delirium. * pregnancy. * patient is unwilling to participate or provide informed consent. * high baseline narcotic baseline requirements that would skew the baseline impact on post-op opiate pain requirements.
megakaryocytic progenitor cells for prophylaxis and treatment of thrombocytopenia

Conditions: Hematological Diseases; Thrombocytopenia

Summary: the purpose of this study is to evaluate the efficacy of ex vivo generated megakaryocytic progenitor cells (mps) in prophylaxis and treatment of thrombocytopenia caused by chemotherapy in patients with acute leukemia (al).

thrombocytopenia is a common and potentially fatal complication of chemotherapy and hematopoietic stem cell transplantation. owing to the short storage time and increased demand of platelets from unrelated donors, a constant shortage in the supply of platelets has become an important medical and society challenge. therefore, investigation of alternative sources of platelets would be beneficial. hematopoietic stem cells (hscs) can be used to generate functional megakaryocytic progenitors (mps), megakaryocytes, and platelets on a large scale. functional mps and platelets have successfully been produced in vitro from cd34+ hematopoietic cells from bone marrow, cord blood, and peripheral blood. several studies have reported that transplantation of in vitro auto-producing mps can promote platelet recovery after high-dose therapy and hsc transplantation. umbilical cord blood is an abundant source of hscs. in vitro large scale production of mps from cord blood could represent an effective platelet substitute. theoretically, the additional transplantation of ex vivo generated progenitor and post-progenitor cells might lead to the production of sufficient numbers of mature functional cells within a few days after transplantation.

Eligibility criteria:
inclusion criteria: * age：14-65 years * achieve complete remission of acute leukemia * the first course of consolidation chemotherapy * ecog grades 0 or 1 * expected survival time ≥ three months * subjects (or their legally acceptable representatives) must have signed an informed consent document. exclusion criteria: * cardiac dysfunction (particularly congestive heart failure), hepatic abnormalities (bilirubin ≥ 3 mg/dl, aminotransferase\> 2 times the upper limit of normal), renal dysfunction (creatinine clearance rate \< 30 ml/min) * any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure) * patients with any conditions not suitable for the trial (investigators' decision)

Keywords: megakaryocytic progenitor products hematological diseases thrombocytopenia
comparing efficacy and safety of tjo-083 in dry eye diseases patients

Conditions: Dry Eye; Dry Eye Syndromes

Summary: in patients with dry eye syndrome, the test drug(tjo-083) or the control drug is administered for 12 weeks, and the corneal staining of each group would be evaluated. the purpose of this clinical study is to demonstrate that the test drug is not clinically inferior to the control drug.


Eligibility criteria:
inclusion criteria: * male or female, age 20 or over * has dry eye symptoms (minimum 3 months) * screening both eyes, the corrected visual acuity is 0.2 or more * written informed consent to participate in the trial exclusion criteria: * the patients who treated with topical nsaids/hyaluronate sodium ophthalmic solutions within 2 weeks of randomized visits. * the patients with systemic or ocular disorders affecting the test results(ocular surgery, trauma, or disease) within 2 months of screening visits. * intraocular pressure(iop)\> 21 mmhg * patients with contact lens
efficacy of massage versus massage with post isometric relaxation exercises in temporomandibular disorders

Conditions: Pain, Joint

Summary: to determine effectiveness of massage versus massage with post isometric relaxation exercises in temporomandibular disorders for pain and limited joint mobility.


Eligibility criteria:
inclusion criteria: * patients with clinical features with myofascial pain and limited mouth opening fulfilling the axis group i of rdc/tmd criteria, * absence of temporomandibular disc displacement with or without reduction, * good general health (absence of chronic diseases which may affect temporomandibular joint or the masticatory muscles), * full dental arches with natural teeth or missing teeth replaced with fixed dental prostheses exclusion criteria: * earlier splint therapy, * pharmacotherapy (e.g., hormone replacement therapy, oral contraception and antidepressants), * injury of masticatory organ, * undergoing orthodontic treatment, * inflammation in oral cavity (e.g., impacted molars and pulp inflammation) and fibromyalgia
daw1033b2 in obstructive sleep apnea

Conditions: Obstructive Sleep Apnea (OSA)

Summary: obstructive sleep apnea (osa) is common and has major health implications but treatment options are limited. osa patients show a marked reduction in upper airway (ua) dilator muscle activity at sleep onset and this phenomenon leads to increased collapsibility of ua compared to normal subjects. in this protocol the investigators will test the effect of daw1033b2 administered before sleep on osa phenotype traits and osa severity during sleep.


Eligibility criteria:
inclusion criterion: * osa: ahi \> 15 exclusion criteria: * any medical condition other than well controlled hypertension, diabetes, hyperlipidemia * any medication known to influence breathing, sleep/arousal or muscle physiology. * claustrophobia. * inability to sleep supine. * allergy to lidocaine, oxymetazoline hcl, daw1033d. * individuals with underlying cardiac disease, such as arrhythmias. * individuals taking psychiatric medications, or any of the studied medications for medical care. * history of seizures * for women: pregnancy. * history of panic disorder / hyperventilation syndrome / attention deficit-hyperactivity disorder (adhd) / autism
ozone therapy in patients with carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: eswt (extracorporeal shock wave therapy), which has been used in the treatment of musculoskeletal diseases in recent years, has come to the agenda as a new treatment method in carpal tunnel syndrome. although the effectiveness of eswt, splinting and exercise applications in cts patients is known in the literature, studies on the effectiveness of ozone therapy are limited. the aim of this study was to compare the efficacy of ozone therapy and eswt applied in addition to splinting and exercise applications in patients diagnosed with cts. the study will consist of 2 groups. in addition to exercise and splinting, 3 sessions of ozone therapy will be applied once a week to study group.patients in the control group will receive eswt once a week for 3 consecutive weeks in addition to exercise and splinting.

carpal tunnel syndrome (cts) is the most common entrapment neuropathy resulting from compression of the median nerve at the wrist level. various methods are applied in the conservative treatment of cts. these include modification of daily life, splinting, physical therapy modalities and exercise methods. eswt (extracorporeal shock wave therapy), which has been used in the treatment of musculoskeletal diseases in recent years, has come to the agenda as a new treatment method in carpal tunnel syndrome. ozone therapy has trophic effects, analgesic effects, antioxidant, immunomodulator, anti-inflammatory and antitumoral effects. although the effectiveness of eswt, splinting and exercise applications in cts patients is known in the literature, studies on the effectiveness of ozone therapy are limited. the aim of this study was to compare the efficacy of ozone therapy and eswt applied in addition to splinting and exercise applications in patients diagnosed with cts. the study will consist of 2 groups. in addition to exercise and splinting, 3 sessions of ozone therapy will be applied once a week to study group.patients in the control group will receive eswt once a week for 3 consecutive weeks in addition to exercise and splinting. ultrasonographic examinations of the median nerve cross-sectional area will be performed using a logiq p5 (healthcare ultrasound, korea) and a high frequency 7-12 mhz linear probe. a hand dynamometer will be used to assess the grip strength of the hand.

Eligibility criteria:
inclusion criteria: * patients between the ages of 18-65 who have been complaining for at least 3 months * diagnosed with mild or moderate carpal tunnel syndrome exclusion criteria: * cervical disc herniation or radiculopathy, * brachial plexus lesion * previous hand or neck surgery * pregnancy, * history of fracture at the wrist level * inflammatory rheumatic disease

Keywords: carpal tunnel syndrome eswt ozone therapy
evaluation of the antipruritic effect of pac-14028 cream in skin pruritus

Conditions: Skin Pruritus

Summary: the objective of this study was to find a clinically appropriate dose of pac-14028 cream by comparatively evaluating the efficacy and safety of pac-14028 cream of amorepacific corporation in patients with dermal pruritus.


Eligibility criteria:
inclusion criteria: * male and female patients at the age of 20 to 65 years old (both inclusive) * pruritus test ≥ 5cm (10cm visual analogue scale \[vas\]) at baseline * eczema or dry skin on the study drug application site * women of childbearing potential should have a negative urine pregnancy test at screening and agree to employ an effective method of birth control (surgical sterilization or oral contraceptives, barrier method with spermicides, intrauterine device, etc.) during the study period. * voluntarily signed written informed consent forms for study participation. exclusion criteria: * pruritus due to other medical (liver disease, renal failure, etc.), psychotic, or neuropathic causes rather than as a skin disease. * chronic skin diseases such as malignant tumor or chronic urticaria, among skin diseases. * simple pruritus caused by allergic substances such as scabies or insect bites. * presence of symptoms of generalized infection at the time of study participation. * previous local treatment or antibiotics administration for pruritus within 7 days prior to study participation. * previous use of oral steroids within 1 month and local steroids within 2 weeks prior to study participation. * history of physical treatment for pruritus, including phototherapy, within 1 month prior to study participation. * patients who are treated with prohibited concomitant drugs or considered to inevitably require treatment with prohibited concomitant drugs during the study period. * renal function impairment with creatinine level * hepatic function impairment with aspartate aminotransferase (ast)/ alanine aminotransferase (alt) * pregnant and lactating women * participation in another clinical study within 1 month prior to screening. * patients considered ineligible for study participation by the principal investigator or sub-investigator for other reasons; pruritus due to other medical (liver disease, renal failure, etc.), psychotic, or neuropathic causes rather than as a skin disease.
18f-flt-pet in breast cancer (mk-0000-139)

Conditions: Breast Cancer

Summary: this study correlated changes from baseline in ki-67, an immunohistochemical marker of cell proliferation, with changes from baseline in tumor uptake of 3'-deoxy-3'\[18f\]-fluorothymidine (18f-flt) following the first cycle of treatment with standard of care neo-adjuvant therapy in participants with breast cancer.


Eligibility criteria:
inclusion criteria: * has newly-diagnosed stage iib/iiia/iiib locally advanced breast cancer * is eligible for pre-operative (neo-adjuvant) chemotherapy exclusion criteria: * has a contraindication to magnetic resonance imaging (mri) * any condition that would limit ability to undergo mri or pet scans * is a nursing mother * has moderate to end-stage renal disease and is not on dialysis or has renal failure on chronic dialysis